Nasdaq1mon
Novo Nordisk A/S: Once-weekly Mim8 is well-tolerated and efficacious in children living with haemophilia A with and without inhibitors
There are different types of haemophilia, which are characterised by the type of clotting factor protein that is defective or missing. Haemophilia A is caused by a missing or defective clotting ...
THE WEEK8mon
A 'transformative' gene therapy for haemophilia B
The NHS can now offer patients with a rare blood disorder a "transformative" new treatment after the UK's medicines watchdog gave its funding the green light. Around 200 people with haemophilia B ...
pharmaphorum2d
Pfizer's haemophilia B gene therapy meets phase 3 primary endpoint
capsid (protein shell) and a high-activity human coagulation FIX gene. The purpose of this gene therapy is for those people living with haemophilia B, once treated, to be able to produce FIX via ...
PMLiVE23d
Sobi receives MHRA approval for Altuvoct in severe or moderate haemophilia A
Haemophilia is a rare condition resulting from insufficient levels of functioning factor VIII, a protein that is essential for blood clotting. Patients can experience bleeding episodes that can cause ...